TALi Digital (ASX:TD1) - Managing Director, Glenn Smith - The Market Herald

" TALi Digital (ASX:TD1) partnership goes live

TALi Digital’s (TD1) partnership with Times Group of India has gone live to the Indian consumer market ahead of schedule.
AnteoTech (ASX:ADO) - CEO, Derek Thomson - The Market Herald

" AnteoTech (ASX:ADO) receives CE Mark approval for COVID-19 test

AnteoTech (ADO) has received Conformitè Europëenne (CE) Mark registration for its rapid test platform and COVID-19 test.
Imugene (ASX:IMU) - CEO, Leslie Chong - The Market Herald

" Imugene (ASX:IMU) presents key findings to leading cancer research association

Imugene (IMU) presented key findings from its HER-Vaxx immunotherapy and CF33 oncolytic virus programs at the American Association for Cancer Research’s annual meeting.
ResApp Health (ASX:RAP) - CEO & Managing Director, Dr Tony Keating - The Market Herald

" ResApp Health (ASX:RAP) raises $5.5M

ResApp Health (RAP) has received firm commitments to raise $5.5 million through a placement.
Opyl (ASX:OPL) - CEO, Michelle Gallaher - The Market Herald - The Market Herald

" Opyl (ASX:OPL) buys back unmarketable shares

Medical tech support provider Opyl (OPL) has completed an off-market share buy-back facility for eligible shareholders who held unmarketable parcels in the company
Universal Biosensors (ASX:UBI) - CEO, John Sharman - The Market Herald

" Universal Biosensors (ASX:UBI) takes up supply agreement with U.S. life sciences company

Universal Biosensors (UBI) has entered an exclusive agreement with U.S.-based Lubris Biopharma for the supply of Lubricin for UBI’s diagnostic products.
Kazia Therapeutics (ASX:KZA) - CEO, Dr James Garner (centre left) - The Market Herald

" Kazia Theraputics (ASX:KZA) to present data for phase II study of paxalisib in brain cancer patients

Kazia Theraputics (KZA) has released data from its ongoing phase two study of its paxalisib candidate in glioblastoma — the most common and
Visioneering Technologies (ASX:VTI) - CEO, Dr Stephen Snowdy - The Market Herald

" Visioneering Technologies (ASX:VTI) closes oversubscribed SPP

Medical device company Visioneering Technologies (VTI) has closed its security purchase plan after raising more than expected.
Immutep (ASX:IMM) - CEO, Marc Voigt - The Market Herald

" Immutep (ASX:IMM) secures U.S. Fast Track designation for efti treatment

Immutep (IMM) has received Fast Track designation in the U.S.
Neuren Pharmaceuticals (ASX:NEU) gets Ethics Committee green light for upcoming clinical trial

" PharmAust (ASX:PAA) receives $750k R&D rebate from ATO

Clinical-stage oncology company PharmAust (PAA) has received a research and development (R&D) rebate of just over $750,000 through the R&D Tax Incentive Scheme.